Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Flibanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.90 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.90 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.90 |
| ▸ | HTR1A | P08908 | 6/20 | 0.90 |
| ▸ | DRD3 | P35462 | 2/20 | 0.90 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.90 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.90 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.90 |
| ▸ | DRD1 | P21728 | 1/20 | 0.90 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.90 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.90 |
| ▸ | HTR7 | P34969 | 8/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flibanserin SCHEMBL247579 | 0.95 | HTR1A (1.00) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL29399513 | 0.95 | HTR1A (1.00) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL30249132 | 0.95 | HTR1A (1.00) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL19743166 | 0.94 | HTR1A (0.98) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL19743151 | 0.94 | HTR1A (0.98) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL2526226 | 0.94 | HTR1A (0.98) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL563586 | 0.94 | HTR1A (0.98) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL2525812 | 0.92 | HTR1A (0.90) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| SCHEMBL8123196 | 0.91 | HTR1A (0.92) | HTR1ADRD3ABCB11ADRA2AADORA3 | |
| Flibanserin SCHEMBL2524720 | 0.91 | HTR1A (0.87) | HTR1ADRD3ABCB11ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546141-B2 | Salts | SPROUT PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-20150126524-A1 | Salts | SPROUT PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | claimed |
| US-20120322810-A9 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | claimed |
| US-20120122883-A1 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2376457-A2 | CRYSTALLINE SALT FORMS OF FLIBANSERINE | Boehringer Ingelheim International GmbH (DE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010079045-A2 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| US-9546141-B2 | Salts | SPROUT PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150126524-A1 | Salts | SPROUT PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20120322810-A9 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120122883-A1 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2376457-A2 | CRYSTALLINE SALT FORMS OF FLIBANSERINE | Boehringer Ingelheim International GmbH (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010079045-A2 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122883-A1 | NEW SALTS | FLNB, FLNA, SLC10A1 | ADRA1A 775/4885OPRM1 2079/4885KCNH2 963/4885 |
| US-20120322810-A9 | NEW SALTS | FLNB, FLNA, SLC10A1 | ADRA1A 775/4885OPRM1 2079/4885KCNH2 963/4885 |
| US-20150126524-A1 | Salts | FLNB, FLNA, SLC10A1 | ADRA1A 484/4885OPRM1 1612/4885KCNH2 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.